NCT01285518 - Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05231023

0.5 mg QD IV x 1 day

DRUG

PF-05231023

1.5 mg QD IV x 1 day

DRUG

PF-05231023

5 mg QD IV x 1 day

DRUG

PF-05231023

15 mg QD IV x 1 day

DRUG

PF-05231023

50 mg QD IV x 1 day

DRUG

PF-05231023

100 mg QD IV x 1 day

DRUG

PF-05231023

200 mg QD IV x 1 day

OTHER

Placebo

0.9% w/v sodium chloride injection, USP QD IVx 1 day

Trial Locations (5)

Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Miramar

Elite Research Institute, Miami

Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.), Fort Meyers

Cetero Research, San Antonio

Profil Institute for Clinical Research, Inc., Chula Vista